CoChat

SAT-140 A Drug-Drug Interaction Trial of Oral Semaglutide with Levothyroxine and Multiple Coadministered Tablets

Open access
Hauge, Camilla, Breitschaft, Astrid, Hartoft-Nielsen, Marie-Louise, Jensen, Simon, Bækdal, Tine · 2019 · Journal of the Endocrine Society
Cited by 15

The DOI matches its Crossref record.

Abstract

Introduction: Oral semaglutide contains the GLP-1 analog semaglutide co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). Aims: This trial investigated (A) the effect of oral semaglutide and SNAC alone on the pharmacokinetics (PK) of levothyroxine (thyroxine), a frequently used oral medication with similar dosing instructions to oral semaglutide, and (B) the effect of multiple co-administered tablets on oral semaglutide PK. Methods: This was a 2-part, open-label, one-sequence crossover trial in 45 healthy subjects. Part A comprised three periods during which subjects received single-dose thyroxine 600 μg alone, with SNAC 300 mg, and with oral semaglutide 14 mg at steady-state. Primary endpoint was area under the total thyroxine (T4) serum concentration-time curve (0-48 h) after thyroxine, baseline-corrected for endogenous total T4 (bcAUC0-48h,T4). No effect of oral semaglutide or SNAC alone was declared if the 90% CI for the treatment ratio (thyroxine ± oral semaglutide or SNAC) was entirely within the pre-defined interval (0.80-1.25). In part B, oral semaglutide 14 mg at steady-state was co-administered with 5 placebo tablets (used as model tablets) once-daily for 5 weeks. Primary endpoint was area under the semaglutide plasma concentration-time curve during a 0-24 h dosing interval at steady state (AUC0-24h); no effect was confirmed if the 90% CI for the treatment ratio (oral semaglutide ± placebo) was entirely within the pre-defined interval (0.7000-1.4286). Safety and tolerability were also assessed. Results: In part A, co-administration of steady-state oral semaglutide with thyroxine resulted in a 33% increase in bcAUC0-48h,T4; the 90% CI for the treatment ratio was not within the no effect interval. Oral semaglutide had no effect on baseline-corrected maximum total T4 concentration (bcCmax,T4). Co-administration of SNAC alone did not increase exposure of total T4. In part B, co-administration of multiple tablets with steady-state oral semaglutide resulted in decreased semaglutide AUC0-24 (34%) and Cmax (32%); part of the treatment ratio 90% CIs were not within the no effect interval for both endpoints. The safety profile was as expected for GLP-1 receptor agonists with gastrointestinal adverse events the most frequent. Conclusion: PK of thyroxine were influenced by co-administration of steady-state oral semaglutide. However, no change in clinical practice is required as close monitoring of co-administered thyroxine is already part of medical guidance. No obvious effect was seen with SNAC alone so increased thyroxine exposure may be due to the known gastric emptying delaying effect of the GLP-1 component. Absorption of oral semaglutide is affected by co-administration with multiple tablets (5), which is addressed in clinical dosing guidance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/js.2019-sat-140

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 15

Metadata

Authors
Hauge, C., Breitschaft, A., Hartoft-Nielsen, M.-L., Jensen, S., & Bækdal, T.
Venue
Journal of the Endocrine Society
Published
2019-04
Volume
3
Issue
Supplement_1
ISSN
2472-1972 (ISSN-L)
OpenAlex
W2944042183
Cited by
15
References
0
FWCI
2.85
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SAT-140 A Drug-Drug Interaction Trial of Oral Semaglutide with Levothyroxine and Multiple Coadministered Tablets. https://app.cochat.ai/papers/10.1210/js.2019-sat-140
The paper
Hauge, C., Breitschaft, A., Hartoft-Nielsen, M.-L., Jensen, S., & Bækdal, T. (2019). SAT-140 A Drug-Drug Interaction Trial of Oral Semaglutide with Levothyroxine and Multiple Coadministered Tablets. Journal of the Endocrine Society. https://doi.org/10.1210/js.2019-sat-140

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.